Lixte Biotechnology Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIXT research report →
Price Chart
About the company
Lixte Biotechnology Holdings, Inc. is a drug discovery company focused on developing new treatments. It employs biomarker technology to identify crucial enzyme targets associated with serious, widespread diseases, then designs innovative compounds to act upon these targets.
- CEO
- Geordan G. Pursglove
- IPO
- 2007
- Employees
- 3
- HQ
- Boca Raton, FL, US
Get TickerSpark's AI analysis on LIXT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-5,107,621
- Net Income
- $-6,009,520-67.6%
- EPS
- $-1.26+20.8%
- OCF Growth
- +3.0%
- FCF Growth
- +3.0%
- 52W High
- $8.38
- 52W Low
- $2.02
- 50D MA
- $5.83
- 200D MA
- $4.31
- Beta
- 1.25
- RSI (14)
- 34
- Avg Volume
- 238.59K
No earnings-call transcripts are available for LIXT yet.
- Free Float
- 89.6%
- Shares Outstanding
- 12.36M
- Float Shares
- 11.07M
of shares held by institutions
11 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 1 ETFs
Biggest fund positions in LIXT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Stazzone Peter | other | 50,000 |
| Jul 1, 26 | Sawyer Jason David | other | 40,000 |
| Jul 1, 26 | Pursglove Geordan Garrett | other | 350,000 |
| Jul 1, 26 | Primus Guy Warren | other | 15,000 |
| Jul 1, 26 | Holloway Michael Andrew | other | 15,000 |
| Jul 1, 26 | Felix Lourdes | other | 30,000 |
| Jul 1, 26 | Travaglini John Francis | other | 0 |
| May 29, 26 | Porter Stuart D | other | 25,000 |
| May 29, 26 | Porter Stuart D | other | 0 |
| Apr 15, 26 | Pursglove Geordan Garrett | other | 350,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LIXT coverage
Recent articles, reports, and earnings notes.
No research on LIXT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LIXT report →AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD
prnewswire.com · Jul 6
LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
globenewswire.com · Jul 6
LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
globenewswire.com · Jul 6
LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS
globenewswire.com · Jul 2
LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS
globenewswire.com · Jul 2
LIXTE Joins Russell Microcap Index
globenewswire.com · Jun 26
LIXTE Joins Russell Microcap Index
globenewswire.com · Jun 26
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
globenewswire.com · Jun 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.